Candel Therapeutics (CADL) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 51.8% versus a loss of 11.6%. Over five years, CADL leads with a +1.1% price change compared with -88.3% for GYRE. Candel Therapeutics is the larger company by market cap ($760.6 million vs $746.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | GYRE |
|---|---|---|
| Share price | $9.94 | $7.04 |
| Market cap | $760.59M | $746.48M |
| 1-day change | +2.90% | +4.14% |
| YTD return | +75.93% | -0.28% |
| 1-year return | +51.76% | -11.56% |
| 5-year return | +1.12% | -88.27% |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $-1.50 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $9.42 |
| 52-week low | $4.35 | $5.44 |
| Distance from 52-week high | -29.00% | -25.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +118.81% | +165.20% |
| Average volume | 1.20M | 106.08K |
| Shares outstanding | 76.52M | 106.03M |
| Employees | 55 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed GYRE by 63.3 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
CADL vs GYRE FAQ
Which is bigger, Candel Therapeutics or Gyre Therapeutics?
Candel Therapeutics (CADL) is larger, with a market capitalization of $760.59M compared with $746.48M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, CADL or GYRE?
CADL returned +51.76% over the past 12 months, compared with -11.56% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Gyre Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics and Biotechnology: Pharmaceutical Preparations for Gyre Therapeutics.